Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $6 to $4.
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $6 to $4.